08:00 , Jan 11, 2010 |  BC Week In Review  |  Financial News

Revance completes venture financing

Revance Therapeutics Inc. , Newark, Calif.   Business: Dermatology   Date completed: 1/4/10   Type: Venture financing   Raised: $25 million   Investors: Essex Woodlands Health Ventures; Vivo Ventures; Technology Partners; Shepherd Ventures; Palo Alto...
01:27 , Jan 5, 2010 |  BC Extra  |  Financial News

Revance raises $25 million

Revance Therapeutics Inc. (Newark, Calif.) raised $25 million in a first close of a planned $35 million series D round led by existing investor Essex Woodlands Health Ventures. Existing investors Vivo Ventures; Technology Partners; Shepherd...
00:38 , Oct 7, 2009 |  BC Extra  |  Financial News

Inviragen, SingVax merge, raise $15M

Inviragen Inc. (Fort Collins, Colo.) merged with fellow vaccines company SingVax Pte. Ltd. (Singapore) and raised $15 million in a Series A round. New investors Charter Life Sciences; Venture Investors; and Phillip Private Equity joined...
07:00 , Sep 29, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Artisan Pharma Inc. Waltham, Mass. Technology: Recombinant human thrombomodulin ( ART-123 ) Disease focus: Cardiovascular Clinical status: Phase IIb Founded: 2006 as a spinout of Asahi Kasei Pharma Corp. University collaborators: Undisclosed Corporate partners: Asahi...
07:00 , Mar 31, 2008 |  BioCentury  |  Finance

Ebb & Flow

VaxGen and oncology company Raven caved under the weight of shareholder disapproval last week and terminated their merger plans. The deal had been scheduled for a shareholder vote on Friday, but was pulled due to...
00:19 , Mar 27, 2008 |  BC Extra  |  Financial News

Alexza raises $10 million

Alexza (NASDAQ:ALXA) raised $10 million in a registered direct offering of 1.3 million shares to BioOne Capital at $8. The price is a 16% premium to Alexza's close of $6.92 on Wednesday. The shares were...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Qiagen, BioOne Capital Pte. Ltd. deal

Diagnostic company QIA and BioOne Capital formed a JV to develop molecular diagnostics for infectious and genetic diseases in Singapore. Dx Assays Pte. Ltd. is expected to be operational by early 2008. QIA will provide...
08:00 , Dec 10, 2007 |  BioCentury  |  Finance

Ebb & Flow

Genentech shares hit their lowest level since early 2005 last week, shedding $7.76 (10%) to reach $68.49 and lopping off more than $8 billion of the company's market cap to $72 billion. The dive came...
08:00 , Dec 10, 2007 |  BioCentury  |  Strategy

Qiagen's Singapore play

Qiagen N.V. announced plans last week to establish a Singaporean joint venture that will combine its expertise in the field of assay development with BioOne Capital Pte. Ltd.'s inside access to local research institutions and...
01:14 , Dec 4, 2007 |  BC Extra  |  Company News

Qiagen, BioOne form JV to develop assays

Diagnostic company Qiagen (FSE:QIA; QGEN) and BioOne Capital (Singapore) formed a JV to develop molecular diagnostics for infectious and genetic diseases in Singapore. Dx Assays is expected to be operational by early 2008. BioOne Capital...